EWA LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,174 shares of the biopharmaceutical company's stock, valued at approximately $356,000.
Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares during the last quarter. Whipplewood Advisors LLC purchased a new position in Gilead Sciences during the 4th quarter worth approximately $35,000. Synergy Investment Management LLC purchased a new position in Gilead Sciences during the 4th quarter worth approximately $40,000. Lee Danner & Bass Inc. acquired a new position in Gilead Sciences during the fourth quarter worth approximately $41,000. Finally, Investment Research & Advisory Group Inc. lifted its stake in Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Insider Buying and Selling at Gilead Sciences
In other news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the completion of the transaction, the chief financial officer now owns 168,174 shares in the company, valued at approximately $17,893,713.60. This trade represents a 1.46% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 48,500 shares of company stock worth $5,236,245. Insiders own 0.27% of the company's stock.
Gilead Sciences Price Performance
Shares of NASDAQ GILD traded down $2.31 during midday trading on Monday, hitting $106.19. The company had a trading volume of 8,170,901 shares, compared to its average volume of 7,663,618. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The business has a 50-day simple moving average of $106.16 and a two-hundred day simple moving average of $102.88. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96. The firm has a market capitalization of $132.09 billion, a price-to-earnings ratio of 22.36, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.32) earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.
Analyst Ratings Changes
GILD has been the topic of a number of research reports. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Bank of America upped their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $110.55.
Read Our Latest Research Report on GILD
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
